Found: 59
Select item for more details and to access through your institution.
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00915-6
- By:
- Publication type:
- Article
Hematopoiesis under telomere attrition at the single-cell resolution.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-27206-7
- By:
- Publication type:
- Article
Hematopoiesis under telomere attrition at the single-cell resolution.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-27206-7
- By:
- Publication type:
- Article
Phase 1/2 study of CPX‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 3, p. 898, doi. 10.1111/bjh.19193
- By:
- Publication type:
- Article
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 4, p. 581, doi. 10.1111/bjh.19060
- By:
- Publication type:
- Article
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 3, p. 378, doi. 10.1111/bjh.17689
- By:
- Publication type:
- Article
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 792, doi. 10.1002/ajh.27236
- By:
- Publication type:
- Article
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1780, doi. 10.1002/ajh.27070
- By:
- Publication type:
- Article
Performance of IPSS‐M in patients with myelodysplastic syndrome after hypomethylating agent failure.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. E281, doi. 10.1002/ajh.27043
- By:
- Publication type:
- Article
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. E91, doi. 10.1002/ajh.26858
- By:
- Publication type:
- Article
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1599, doi. 10.1002/ajh.26731
- By:
- Publication type:
- Article
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1560, doi. 10.1002/ajh.26724
- By:
- Publication type:
- Article
Prediction of survival with intensive chemotherapy in acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 865, doi. 10.1002/ajh.26557
- By:
- Publication type:
- Article
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS).
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E246, doi. 10.1002/ajh.26182
- By:
- Publication type:
- Article
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. 241, doi. 10.1002/ajh.26047
- By:
- Publication type:
- Article
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. E50, doi. 10.1002/ajh.26044
- By:
- Publication type:
- Article
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-46424-3
- By:
- Publication type:
- Article
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 1983, doi. 10.3390/cancers15071983
- By:
- Publication type:
- Article
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 5, p. 1, doi. 10.1002/cam4.7093
- By:
- Publication type:
- Article
Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.582213
- By:
- Publication type:
- Article
Management of myelodysplastic syndromes after failure of response to hypomethylating agents.
- Published in:
- Therapeutic Advances in Hematology, 2019, v. 10, p. 1, doi. 10.1177/2040620719847059
- By:
- Publication type:
- Article
Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. 732, doi. 10.1016/j.clml.2024.06.001
- By:
- Publication type:
- Article
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 9, p. 629, doi. 10.1016/j.clml.2024.04.007
- By:
- Publication type:
- Article
MDS-439: A Simplified Three-Marker Panel for Myelodysplastic Syndrome Prognostic Outperforms the Well-Established Revised International Prognostic Scoring Systems (IPSS-R).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S351, doi. 10.1016/S2152-2650(21)01813-9
- By:
- Publication type:
- Article
MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S339, doi. 10.1016/S2152-2650(21)01791-2
- By:
- Publication type:
- Article
Poster: MDS-439: A Simplified Three-Marker Panel for Myelodysplastic Syndrome Prognostic Outperforms the Well-Established Revised International Prognostic Scoring Systems (IPSS-R).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S229, doi. 10.1016/S2152-2650(21)01442-7
- By:
- Publication type:
- Article
Poster: MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S226, doi. 10.1016/S2152-2650(21)01427-0
- By:
- Publication type:
- Article
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. 338, doi. 10.1016/j.clml.2020.12.025
- By:
- Publication type:
- Article
A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S88, doi. 10.1016/j.clml.2016.07.124
- By:
- Publication type:
- Article
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00487-3
- By:
- Publication type:
- Article
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01476-8
- By:
- Publication type:
- Article
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 9, p. 1503, doi. 10.1093/cid/ciac230
- By:
- Publication type:
- Article
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 5, p. 405, doi. 10.1007/s11899-021-00643-3
- By:
- Publication type:
- Article
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 12, p. E326, doi. 10.1002/ajh.25991
- By:
- Publication type:
- Article
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1399, doi. 10.1002/ajh.25950
- By:
- Publication type:
- Article
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. 612, doi. 10.1002/ajh.25769
- By:
- Publication type:
- Article
A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 1, p. 74, doi. 10.1002/ajh.25318
- By:
- Publication type:
- Article
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 1, p. 129, doi. 10.1002/ajh.24930
- By:
- Publication type:
- Article
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 7, p. 599, doi. 10.1002/ajh.24735
- By:
- Publication type:
- Article
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy.
- Published in:
- Cold Spring Harbor Molecular Case Studies, 2021, v. 7, n. 3, p. 1, doi. 10.1101/mcs.a006084
- By:
- Publication type:
- Article
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
- Published in:
- Acta Haematologica, 2022, v. 145, n. 5, p. 529, doi. 10.1159/000525566
- By:
- Publication type:
- Article
Treating Leukemia in the Time of COVID-19.
- Published in:
- Acta Haematologica, 2021, v. 144, n. 2, p. 132, doi. 10.1159/000508199
- By:
- Publication type:
- Article
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01229-z
- By:
- Publication type:
- Article
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice